GlassScriptPhysician profile
Scott D Sherman
NPI 1104074046
$11,966.77
in general payments reported to CMS, 2019-2025
37 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,772 · 2020: $857 · 2021: $2,267 · 2022: $912 · 2023: $1,271 · 2024: $1,186 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,159.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,576.74 | 2019-2025 | General - Pain Management |
| Nevro Corp. | $1,735.11 | 2019-2024 | Senza |
| Relievant Medsystems, INC. | $1,158.17 | 2019-2021 | |
| Medtronic, INC. | $1,022.61 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Collegium Pharmaceutical, INC. | $737.95 | 2019-2025 | Belbuca, Xtampza |
| Vertos Medical, INC. | $495.35 | 2020-2023 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $460.43 | 2019-2024 | Ztlido |
| Medtronic USA, INC. | $449.33 | 2019-2020 | |
| Stimwave Technologies Incorporated | $433.41 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.38 | 2019-2025 | Relistor |
| Abbvie INC. | $384.06 | 2021-2023 | Botox |
| Vertiflex, INC. | $221.77 | 2019 | |
| Amgen INC. | $217.00 | 2019-2022 | |
| Grt US Holding, INC. | $188.66 | 2021-2022 | |
| Allergan, INC. | $183.89 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $152.78 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $140.45 | 2019 | |
| Flowonix Medical Incorporated | $112.85 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $110.13 | 2019-2021 | |
| Protega Pharmaceutials INC | $102.90 | 2024-2025 | Roxybond |
| Pfizer INC. | $101.68 | 2019-2021 | |
| Abbott Laboratories | $97.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.41 | 2019-2021 | |
| Lilly USA, LLC | $69.72 | 2019-2021 | |
| Ibsa Pharma INC. | $43.00 | 2021 | |
| Hikma Pharmaceuticals USA | $40.34 | 2022 | |
| Camber Spine Technologies LLC | $39.17 | 2021 | |
| Daiichi Sankyo INC. | $38.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.79 | 2021 | |
| Foundation Fusion Solutions, LLC | $21.56 | 2025 | |
| Bioventus LLC | $19.71 | 2022 | |
| Spinal Simplicity, LLC | $19.32 | 2022 | |
| Redhill Biopharma INC. | $18.83 | 2021 | |
| Depuy Synthes Sales INC. | $17.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2022 | |
| Assertio Therapeutics, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.